Vimta Labs

Vimta Labs

655.00
+33.10
(5.32%)
ann
Q1 Quarterly Results are out. Check out the updated financials2 days ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
Market Cap
2,917.42 Cr
EPS
18.51
PE Ratio
45.13
Dividend Yield
0.16 %
Industry
Healthcare
52 Week High
902.65
52 Week Low
285.05
PB Ratio
8.08
Debt to Equity
0.06
Forecast For
Actual

Company News

View All News
Caret
positive
VIMTA Labs reported Q2 revenue of 1 billion rupees, up from 847 million rupees in the same period last year. Net profit increased to 199 million rupees from 170 million rupees year-over-year. EBITDA rose to 342 million rupees compared to 299 million rupees previously, though EBITDA margin declined to 33.61% from 35.28% in the prior year period.
positive
Vimta Labs Limited achieved its highest ever quarterly revenue of INR 993 million in Q1 FY2026, representing a 31.4% year-on-year growth from INR 756 million in the previous year. EBITDA increased 33.1% to INR 354 million with margins at 35.7%, while profit after tax grew 35.9% to INR 189 million with 19% margins. The company successfully completed an unannounced US FDA GCP inspection with no Form 483 observations and received cGMP compliance letter from ANSM EMA. Pharmaceutical testing and research services contribute 65-70% of revenue, food testing accounts for 20%, and electronics/electrical testing represents 10%. The Board approved a 1:1 bonus issue. Equipment procurement is progressing for biologics contract research services, expected to commercialize from Q1 FY2027. The company maintains a debt-free balance sheet with cash equivalents of INR 379.3 million and has completed facility expansion of 200,000 square feet to support future growth.
neutral
Vimta Labs Makes Q1 FY 2025-26 Earnings Call Recording Available OnlineJul 22, 2025
Vimta Labs Limited has published the audio recording of its Q1 FY 2025-26 earnings and investor call on the company's website. The call was held on July 21, 2025, and the recording is accessible through a provided web link. The company disclosed this information to stock exchanges BSE and NSE as part of regulatory requirements.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
615.85
#1 24,815.02
53.43
#1 3,714.20
3.77
#1 496
-36.76
37.91
523.25
12,565.31
28.57
2,946.50
10.53
407
11.34
38.61
189.48
4,310.18
-23.73
17.60
-46.34
-161
-83.93
42.01
655.00
#4 2,917.42
#8 45.13
#4 322.30
#8 0.22
#3 41
#2 112.87
34.27
22.90
338.77
7.18
10.20
#1 126.67
1
#1 493.75
67.45
100.00
235.45
-4.67
806.50
4.78
-56
34.67
54.00
60.00
95.02
#1 -23.80
47.50
17.87
0
-420.00
67.02
19.23
26.30
33.09
84.00
5.00
2
-92.68
50.90
27.60
19.70
-1.48
2.10
40.00
-13
-566.67
57.08
Growth Rate
Revenue Growth
0.22 %
Net Income Growth
-14.94 %
Cash Flow Change
-30.76 %
ROE
-24.97 %
ROCE
-26.21 %
EBITDA Margin (Avg.)
-7.88 %

Quarterly Financial Results

Quarterly Financials
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
45
33
59
59
60
62
76
68
75
80
81
79
83
84
68
75
80
76
85
95
Expenses
38
29
43
42
43
45
57
47
51
55
55
56
58
59
50
53
55
51
57
57
EBITDA
7
4
16
17
17
17
19
21
24
25
26
23
25
25
18
23
25
25
29
38
Operating Profit %
11 %
11 %
27 %
28 %
28 %
27 %
25 %
31 %
31 %
30 %
32 %
28 %
30 %
30 %
24 %
29 %
31 %
32 %
33 %
37 %
Depreciation
5
6
6
6
6
6
6
6
7
7
8
8
8
9
9
8
8
8
8
10
Interest
1
1
0
1
1
0
0
0
1
1
1
1
0
0
1
1
1
1
0
1
Profit Before Tax
0
-2
0
11
10
11
13
16
16
17
18
14
17
16
8
14
16
17
20
28
Tax
0
-1
-8
3
3
3
3
4
4
5
5
4
4
4
2
3
4
4
5
6
Net Profit
0
-2
8
8
8
8
10
12
12
12
13
10
13
12
6
10
12
12
15
22
EPS in ₹
0.03
-0.88
3.41
3.65
3.50
3.65
4.41
5.28
5.36
5.45
5.97
4.62
5.73
5.51
2.86
3.61
5.58
5.54
6.88
9.65

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
Total Assets
246
274
307
362
400
Fixed Assets
138
135
169
175
171
Current Assets
96
111
124
164
158
Capital Work in Progress
2
18
0
12
59
Investments
0
0
0
0
0
Other Assets
106
122
138
175
170
Total Liabilities
246
274
307
362
400
Current Liabilities
58
54
48
57
54
Non Current Liabilities
15
26
26
23
26
Total Equity
173
194
234
282
320
Reserve & Surplus
169
190
230
277
315
Share Capital
4
4
4
4
4

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
Net Cash Flow
3
1
5
20
-17
Investing Activities
-21
-32
-38
-57
-76
Operating Activities
24
37
59
88
61
Financing Activities
-1
-5
-17
-11
-2

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
37.46 %
37.46 %
37.46 %
37.46 %
37.46 %
37.46 %
37.46 %
37.25 %
37.24 %
37.23 %
37.01 %
36.98 %
36.92 %
36.89 %
36.89 %
36.76 %
36.70 %
36.67 %
35.99 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.74 %
0.00 %
5.13 %
5.16 %
3.31 %
3.81 %
3.66 %
3.49 %
4.33 %
DIIs
0.00 %
0.00 %
1.29 %
1.48 %
1.48 %
1.48 %
1.48 %
2.13 %
2.14 %
2.13 %
1.50 %
1.49 %
1.50 %
1.49 %
0.00 %
1.16 %
1.43 %
1.42 %
0.87 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
29.08 %
29.45 %
28.48 %
27.35 %
27.07 %
26.99 %
26.79 %
25.06 %
25.19 %
24.60 %
25.00 %
25.15 %
23.08 %
23.13 %
26.53 %
25.09 %
25.17 %
24.02 %
24.62 %
Others
33.46 %
33.09 %
32.77 %
33.71 %
34.00 %
34.07 %
34.27 %
35.56 %
35.43 %
36.04 %
33.75 %
36.38 %
33.37 %
33.33 %
33.27 %
33.18 %
33.03 %
34.40 %
34.18 %
No of Share Holders
12,152
20,928
19,947
19,194
18,332
18,106
18,283
18,916
17,162
17,439
18,429
19,957
18,550
19,054
20,114
21,156
26,183
29,867
55,933

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 1 0.00 2 2 0.00 2 2 2 2 2
Dividend Yield (%) 1.81 0.00 2.01 6.7 0.00 1.27 1.27 0.9 0.4 0.32

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
28 Jun 2021 DIVIDEND Dividend
₹ 2.00 /share
25 Jun 2021 126.95 125.73
18 Jun 2022 DIVIDEND Dividend
₹ 2.00 /share
16 Jun 2022 160.78 157.48
22 Jun 2023 DIVIDEND Dividend
₹ 2.00 /share
21 Jun 2023 191.85 204.38
12 Jul 2024 DIVIDEND Dividend
₹ 2.00 /share
11 Jul 2024 246.90 258.05
18 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Jul 2024 246.90 281.93
08 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Nov 2024 286.40 289.20
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
24 Jan 2025 426.53 433.03
28 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Apr 2025 490.60 543.85
30 May 2025 DIVIDEND Dividend
₹ 2.00 /share
30 May 2025 543.85 491.20
06 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
06 Jun 2025 519.78 475.80
13 Jun 2025 BONUS Bonus
1:1
13 Jun 2025 469.60 501.78
17 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
17 Jul 2025 450.95 473.15
03 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
03 Nov 2025 668.75 725.25

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome3 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation4 days ago
Q2 FY- 2025-26 - Unaudited Financial Results.4 days ago
Board Meeting Outcome for Q2 FY- 2025-26 - Unaudited Financial Results4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Board Meeting Intimation for Q2 FY2025-26- Financial Results - Board Meeting9 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Closure of Trading WindowSep 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 04, 2025
Clarification On Volume MovementSep 03, 2025
Clarification sought from Vimta Labs LtdSep 03, 2025
Update On In-Principle Approval Received From Stock ExchangesSep 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 09, 2025
Announcement under Regulation 30 (LODR)-Credit RatingAug 08, 2025
Clarification On Movement In PriceJul 30, 2025
Clarification sought from Vimta Labs LtdJul 29, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 21, 2025
Clarification On Volume MovementJul 21, 2025
Clarification sought from Vimta Labs LtdJul 21, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 17, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 17, 2025
Results- Financial Results Q1- 30.06.2025Jul 17, 2025
Board Meeting Outcome for Unaudited Financial Results For Quarter Ended 30Th June 2025 (Q1)Jul 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Board Meeting Intimation for The Quarter Ended 30Th June 2025 (Q1)Jul 14, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 30, 2025
Closure of Trading WindowJun 30, 2025
Complete Copy Of MOA & AOAJun 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-AllotmentJun 14, 2025
Cancellation of Board MeetingJun 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Board Meeting Intimation for Allotment Of Bonus Equity Shares.Jun 06, 2025
Revision Of Remuneration Of Executive Directors.Jun 06, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJun 06, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 06, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 06, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.00%
-198
-0.08%
-0.07%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
34.27
ATR(14)
Volatile
32.23
STOCH(9,6)
Neutral
43.01
STOCH RSI(14)
Oversold
19.08
MACD(12,26)
Bearish
-3.34
ADX(14)
Weak Trend
15.21
UO(9)
Bearish
40.15
ROC(12)
Downtrend And Accelerating
-10.06
WillR(14)
Oversold
-94.33